Back to search

Article

Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stress

2023-05-23

Abstract excerpt

<title>Abstract</title><p><bold>Background:</bold>Gemcitabine (GEM)-based chemotherapy is the standard treatment for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1, a key transcription factor in hematopoiesis, also involved in the malignant progression of PDAC, but was unclear in the chemoresistance...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
88e1e16a-3a36-59cf-a597-68fe871b904a
DOI
10.21203/rs.3.rs-2944766/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stressDOI 10.21203/rs.3.rs-2944766/v1
Select a neighboring publication to make it the new centre.